Hurwitz C A, Mounce K G, Grier H E
Maine Children's Cancer Program, Department of Pediatrics, Maine Medical Center, Portland, USA.
J Pediatr Hematol Oncol. 1995 Aug;17(3):185-97. doi: 10.1097/00043426-199508000-00001.
We discuss the history and progress of treatment for acute myelogenous leukemia (AML) in children as it has evolved over the past decade. We review the results of clinical trails for children with AML and examine the major strategies that have contributed to progresses in the treatment of this disease. Prior to the 1970's, nearly every child with AML died. Modern intensive chemotherapy, bone marrow transplantation, and advanced supportive care of critically ill patients have improved the outlook for children with this fatal disease.
Although it represents only 15-20% of all childhood acute leukemias, > 30% of deaths from leukemia are still a consequence of AML, and only 30-40% of children with newly diagnosed AML are expected to achieve a long-term remission. Greater advances in treatment are expected as headway is made in understanding the complex biology of this heterogeneous disease.
我们讨论了儿童急性髓性白血病（AML）在过去十年中的治疗历史与进展。我们回顾了AML患儿的临床试验结果，并审视了推动该疾病治疗取得进展的主要策略。在20世纪70年代之前，几乎每个AML患儿都会死亡。现代强化化疗、骨髓移植以及对危重症患者的先进支持治疗改善了患有这种致命疾病患儿的预后。
尽管AML仅占所有儿童急性白血病的15% - 20%，但白血病导致的死亡中仍有超过30%是由AML引起的，新诊断的AML患儿中预计只有30% - 40%能实现长期缓解。随着对这种异质性疾病复杂生物学的理解取得进展，有望在治疗上取得更大进展。
